Cargando…

Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

BACKGROUND: The 300IR (index of reactivity) 5-grass pollen tablet has favorable short-term and sustained clinical efficacy in patients with grass pollen-induced allergic rhinoconjunctivitis (ARC). Here, we report maintenance of efficacy and safety over 2 years following treatment discontinuation. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Didier, Alain, Malling, Hans-Jørgen, Worm, Margitta, Horak, Friedrich, Sussman, Gordon L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474569/ https://www.ncbi.nlm.nih.gov/pubmed/26097680 http://dx.doi.org/10.1186/s13601-015-0057-8

Ejemplares similares

5 Posttreatment, Long-Term Clinical Efficacy of a 300 IR Sublingual Tablet of 5-Grass Pollen Allergen Extract in Adults With Grass Pollen Induced Allergic Rhinoconjunctivitis
por: Didier, Alain, et al.
Publicado: (2012)

Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study
por: Worm, Margitta, et al.
Publicado: (2014)

161 Efficacy and Safety of 300IR 5-Grass Pollen Sublingual Allergen Immunotherapy Tablets in us Adults With Grass-Pollen Allergic Rhinoconjunctivitis
por: Cox, Linda, et al.
Publicado: (2012)

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment
por: Horak, F, et al.
Publicado: (2009)

Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis
por: Malling, H-J, et al.
Publicado: (2009)

Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study
por: Shah-Hosseini, Kija, et al.
Publicado: (2017)

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
por: Niederberger, Verena, et al.
Publicado: (2018)

Sensitization to cereals and peanut evidenced by skin prick test and specific IgE in food-tolerant, grass pollen allergic patients
por: Martens, Maria, et al.
Publicado: (2011)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults
por: Ruggeri, Matteo, et al.
Publicado: (2013)

Efficacy of Timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC)
por: Hebert, Jacques, et al.
Publicado: (2011)

Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain
por: Antolín-Amerigo, Darío, et al.
Publicado: (2017)

A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy
por: Ciprandi, Giorgio
Publicado: (2015)

Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires
por: Batard, Thierry, et al.
Publicado: (2019)

A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy
por: Massaro, Ilaria, et al.
Publicado: (2017)

Detection of genuine grass pollen sensitization in children by skin testing with a recombinant grass pollen hybrid
por: Douladiris, Nikolaos, et al.
Publicado: (2018)

5-grass-pollen SLIT effectiveness in seasonal allergic rhinitis: Impact of sensitization to subtropical grass pollen
por: van Nunen, Sheryl A., et al.
Publicado: (2022)

P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets
por: Karagiannis, Efstrathios, et al.
Publicado: (2014)

A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis
por: Alesina, Roberta, et al.
Publicado: (2012)

Aerobiological Monitoring and Metabarcoding of Grass Pollen
por: Krinitsina, Anastasia A., et al.
Publicado: (2023)

A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma
por: Murphy, Kevin, et al.
Publicado: (2013)

Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study
por: Pfaar, Oliver, et al.
Publicado: (2015)

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy
por: Zieglmayer, Petra, et al.
Publicado: (2016)

2 Dose Optimizing Study of a Depigmented Polymerized Allergen Extract of Birch Pollen by Means of Conjunctival Provocation Test
por: Sager, Angelika, et al.
Publicado: (2012)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Exposure to grass pollen – but not birch pollen – affects lung function in Swedish children
por: Gruzieva, O., et al.
Publicado: (2015)

Discrimination of grass pollen of different species by FTIR spectroscopy of individual pollen grains
por: Diehn, Sabrina, et al.
Publicado: (2020)

5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study
por: Pastorello, Elide Anna, et al.
Publicado: (2013)

Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study
por: Schäfer, Udo, et al.
Publicado: (2017)

Update about Oralair® as a treatment for grass pollen allergic rhinitis
por: Klimek, L., et al.
Publicado: (2022)

Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax(®)
por: Calderón, Moisés, et al.
Publicado: (2008)

“The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis”
por: Demoly, Pascal, et al.
Publicado: (2015)

A Group-1 Grass Pollen Allergen Influences the Outcome of Pollen Competition in Maize
por: Valdivia, Elene R., et al.
Publicado: (2007)

Sensitization to timothy grass pollen allergenic molecules in children
por: Scaparrotta, Alessandra, et al.
Publicado: (2013)

Differences in grass pollen allergen exposure across Australia
por: Beggs, Paul J., et al.
Publicado: (2015)

Sensitization Profiles of Timothy Grass Pollen in Northern China
por: Xu, Yingyang, et al.
Publicado: (2021)

Personalized Pollen Monitoring and Symptom Scores: A Feasibility Study in Grass Pollen Allergic Patients
por: de Weger, Letty A., et al.
Publicado: (2021)

Clinical Results from Vaccination With Recombinant Grass Pollen Allergens
por: Jutel, Marek, et al.
Publicado: (2006)

Combining Chemical Information From Grass Pollen in Multimodal Characterization
por: Diehn, Sabrina, et al.
Publicado: (2020)

Grass pollen allergy in children and adolescents-symptoms, health related quality of life and the value of pollen prognosis
por: Kiotseridis, Hampus, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4o161ead909cql0q13opmbj0rb